Bigbear Pharmaceutical·Medication Guide

• ​FDA Approves Enasidenib for Relapsed or Refractory Acute Myeloid Leukemia with IDH2 Mutation

  August 1, 2017 — The U.S. Food and Drug Administration (FDA) has approved Enasidenib for the treatment of adult patients with relapsed or refractory a···【Read More】

  Update: 2026-05-08Source: Haiou HealthViews: 183

• FDA Warns That Leukemia Drug Enasidenib May Trigger Differentiation Syndrome

  On November 29, 2018, the U.S. Food and Drug Administration (FDA) issued a warning stating that signs and symptoms of a life-threatening side effect k···【Read More】

  Update: 2026-05-08Source: Haiou HealthViews: 182

• Anagrelide: Prescription Information and Overview

  Anagrelide capsules, for oral administration, were first approved for marketing in the United States in 1997. Anagrelide is a thrombocytopenic agent i···【Read More】

  Update: 2026-05-08Source: Haiou HealthViews: 206

• FDA Approves Osimertinib for EGFR T790M Mutation-Positive Non-Small Cell Lung Cancer

  On November 16, 2015, the U.S. Food and Drug Administration (FDA) granted accelerated approval to an oral medication for the treatment of patients wit···【Read More】

  Update: 2026-05-08Source: Haiou HealthViews: 233

• Osimertinib Receives Full FDA Approval for EGFR T790M Mutation-Positive Non-Small Cell Lung Cancer

  March 31, 2017 — AstraZeneca announced that the U.S. Food and Drug Administration (FDA) has granted full approval to Osimertinib (brand name: Tagrisso···【Read More】

  Update: 2026-05-08Source: Haiou HealthViews: 172

• ​FDA Approves Osimertinib as First-Line Treatment for EGFR-Mutated Non-Small Cell Lung Cancer

  On April 18, 2018, AstraZeneca announced that the U.S. Food and Drug Administration (FDA) has approved the targeted therapy Osimertinib for the first-···【Read More】

  Update: 2026-05-07Source: Haiou HealthViews: 174

• What Diseases Does Osimertinib Treat? Actions and Efficacy of Osimertinib

  Osimertinib is a tyrosine kinase inhibitor used to treat patients with non-small cell lung cancer (NSCLC) whose tumors have been identified—via an FDA···【Read More】

  Update: 2026-05-07Source: Haiou HealthViews: 173

• Osimertinib Approved in the U.S. for Adjuvant Treatment of Early-Stage EGFR-Mutated Non-Small Cell Lung Cancer

  On December 21, 2020, AstraZeneca’s Osimertinib was approved in the United States for the adjuvant treatment of adult patients with early-stage epider···【Read More】

  Update: 2026-05-07Source: Haiou HealthViews: 155

• US Approves Osimertinib in Combination with Chemotherapy for Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer

  On February 19, 2024, AstraZeneca announced that its drug, osimertinib, has received approval in the United States for use in combination with chemoth···【Read More】

  Update: 2026-05-07Source: Haiou HealthViews: 168

• Osimertinib Approved in the US for the Treatment of Patients with Unresectable Stage III EGFR-Mutated Lung Cancer

  September 26, 2024, Cambridge, UK — AstraZeneca’s osimertinib has received approval in the United States for the treatment of adult patients with unre···【Read More】

  Update: 2026-05-07Source: Haiou HealthViews: 170

• Ivosidenib Receives FDA Approval as Monotherapy for Newly Diagnosed Adult Patients with IDH1-Mutated Acute Myeloid Leukemia (Ineligible for Intensive Chemotherapy)

  May 2, 2019 (Global Newswire) — Cambridge, MAAgios Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved its supplem···【Read More】

  Update: 2026-05-06Source: Haiou HealthViews: 193

• Ivosidenib Receives FDA Approval for the Treatment of IDH1-Mutated Cholangiocarcinoma

  August 25, 2021 – BostonServier Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved Ivosidenib for the treatment o···【Read More】

  Update: 2026-05-06Source: Haiou HealthViews: 174

• Ivosidenib in combination with azacitidine receives FDA approval for the treatment of newly diagnosed IDH1-mutant acute myeloid leukemia (AML) patients

  May 25, 2022, BostonServier announced that the U.S. Food and Drug Administration (FDA) has approved ivonidenib in combination with azacitidine for the···【Read More】

  Update: 2026-05-06Source: Haiou HealthViews: 171

• Ivosidenib Approved by FDA for IDH1-Mutant Relapsed or Refractory Myelodysplastic Syndrome (MDS)

  October 24, 2023, Boston, USAServier announced that the U.S. Food and Drug Administration (FDA) has approved ivonidenib for the treatment of patients ···【Read More】

  Update: 2026-05-06Source: Haiou HealthViews: 157

• What diseases does Ivosidenib treat? Indications and Efficacy of Ivosidenib

  Ivosidenib is used to treat acute myeloid leukemia (AML), cholangiocarcinoma, and myelodysplastic syndromes (MDS) in adult patients with isocitrate de···【Read More】

  Update: 2026-05-06Source: Haiou HealthViews: 188